Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism

NCT01220050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Renal Transplant
Secondary Hyperparathyroidism

Interventions

DRUG: Paricalcitol
DRUG: Standard therapy

Sponsor

Mario Negri Institute for Pharmacological Research